13.95  -0.28 (-1.97%)		04-25 16:00
Open: 14.26 High: 14.26 Volume: 6,363		Pre. Close: 14.23 Low: 13.8 Market Cap: 28(M)

Short term
Mid term
Targets	6-month :	18.27	1-year :	19.6
Resists	First :	15.64	Second :	16.78
Pivot price	14.93
Supports	First :	13.8	Second :	11.48
MAs	MA(5) :	14.19	MA(20) :	15.2
	MA(100) :	14.74	MA(250) :	13.09
MACD	MACD :	-0.6	Signal :	-0.5
%K %D	K(14,3) :	15.8	D(3) :	16.3
RSI	RSI(14): 33.5
52-week	High :	17.95	Low :	9.22

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ CNCR ] has closed above bottom band by 15.1%. Bollinger Bands are 37.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	14.27 - 14.36	14.36 - 14.44
Low:	13.62 - 13.71	13.71 - 13.79
Close:	13.81 - 13.96	13.96 - 14.09

The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.

Mon, 26 Jun 2023
Last Week in ETFs: 15 Launches, Closures Continue Rapid Pace - ETF Trends

Thu, 11 May 2023
Where to Be in ETFs for Rising Biotech M&A - Nasdaq

Wed, 15 Mar 2023
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector - InvestorPlace

Fri, 01 Jul 2022
Best Performing ETFs For June 2022 - ETF Focus on TheStreet: ETF research and Trade Ideas - TheStreet

Wed, 11 May 2022
Cancer Drug Developers Plummet After Roche (ROG) Trial Failure - Bloomberg

Wed, 13 Oct 2021
Legend Biotech Hits New 54-Week High - ETF Trends

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Financial Services
Industry: Asset Management
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.